Medical application of Wip1 or Coro1a

By targeting Wip1 protein or promoting Coro1a phosphorylation, regulating the calcium ion pathway of neutrophils and promoting the formation of NET, the shortcomings in the treatment of bacterial infectious diseases in the prior art are solved, and resistance to methicillin is achieved Effective control of Staphylococcus aureus.

CN119015414APending Publication Date: 2024-11-26INST OF ZOOLOGY CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310584284.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art lacks new technical means to treat and prevent infectious diseases, especially for infectious diseases caused by bacteria, such as skin abscesses caused by methicillin-resistant Staphylococcus aureus.

Method used

By targeting Wip1 protein or its domain, inhibiting its activity, or using reagents that promote phosphorylation of Coro1a, activate phospholipase C, regulates the calcium ion pathway of neutrophils, and promotes the formation of NET to capture and kill pathogenic microorganisms.

Benefits of technology

Effectively delay or prevent the occurrence and development of infectious diseases, significantly reduce the formation and size of skin abscesses, and enhance the antibacterial function of neutrophils.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119015414A_ABST
    Figure CN119015414A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and relates to medical application of Wip1 (p53 induced phosphatase 1) and / or Coro1a. Specifically, the invention relates to application of Wip1 as a target spot in preparation of drugs for treating and / or preventing infectious diseases, especially infectious diseases caused by bacteria. The invention provides an experimental basis and a new therapeutic target for the treatment of infectious diseases, and has a good application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine and relates to the medical use of Wip1 (p53-induced phosphatase 1) and / or Coro1a; specifically, it relates to the use of Wip1 and / or Coro1a as targets in the preparation of drugs for treating and / or preventing infectious diseases, especially infectious diseases caused by bacteria. Background Art

[0002] Wild-type p53-induced phosphatase 1 (Wip1, also known as PP2Cδ or PPM1D) is a serine / threonine protein phosphatase that regulates cell function by dephosphorylating serine / threonine residues of signaling pathway proteins. Wip1 has been confirmed to be an oncogene and is expected to become a target for cancer treatment. Wip1 is involved in regulating the differentiation and development of various immune cells, such as neutrophils, T cells, B cells, thymic epithelial cells, and macrophages, and is involved in regulating a variety of immune-related diseases, and has the potential to become a target for disease treatment. Wip1 is preferentially expressed in neutrophils, and there are few reports on its effects on the antibacterial function of neutrophils and its therapeutic effects on infectious diseases.

[0003] Neutrophil extracellular traps (NETs or NETs for short) are a network structure composed of DNA histones and various enzymes such as MPO, elastase and granzyme released by neutrophils when they are stimulated by pathogens, etc., which is one of the ways for neutrophils to resist foreign invasion. NETs are often released when neutrophils die, so the release process of NETs is also considered to be a form of programmed death unique to neutrophils.

[0004] In infectious diseases, NETs have been shown to capture, neutralize, and kill bacteria, fungi, viruses, and parasites, and are believed to prevent the spread of bacteria and fungi. At the same time, studies have also reported that NETs are also involved in the occurrence and development of a variety of non-infectious diseases, such as systemic lupus erythematosus, rheumatoid arthritis, diabetes, atherosclerosis, vasculitis, thrombosis, tumors, wound healing, and trauma. Various inducers or stimulants can induce neutrophils to release NETs, ​​such as PMA, LPS, bacteria, calcium ion activator A23128, ionomycin, uric acid crystals, etc. There are no reports on the relationship between NETs and Wip1.

[0005] Coro1a is a highly conserved actin-binding protein that regulates cellular processes related to the actin cytoskeleton, such as cell division, cell polarization, migration, and phagocytosis. Coro1a has been shown to be phosphorylated by PKC and regulate PLC-γ1 activity, thereby regulating calcium ion pathways. Coro1a is almost exclusively expressed in the hematopoietic system and plays an important role in the immune system, including in regulating Ca2+ in macrophages. 2+ Signal transduction, neutrophil migration, TCR signal transduction, and T lymphocyte activation, migration, survival, and Ca 2+ Coro1a deficiency can lead to severe viral infections, encephalomyelitis, systemic lupus erythematosus, etc., so it may become a potential target for regulating autoimmune diseases.

[0006] At present, new technical means for treating infectious diseases still need to be developed. Summary of the invention

[0007] After in-depth research and creative work, the inventors surprisingly found that Coro1a is a new substrate of Wip1. Knocking out or targeting Wip1 protein with inhibitors will increase the phosphorylated Coro1a, activate the neutrophil calcium ion pathway, promote the formation of neutrophil extracellular traps (NETs), capture and kill pathogenic microorganisms to treat infectious diseases. Therefore, Wip1 and Coro1a can be used as drug targets for treating infectious diseases. The following invention is provided:

[0008] One aspect of the present invention relates to the use of any one of the following (1)-(7) in the preparation of a medicament for treating or preventing an infectious disease in a mammal:

[0009] (1) Wip1 protein or its domain;

[0010] (2) a nucleic acid molecule encoding a Wip1 protein or a domain thereof;

[0011] (3) drugs that inhibit Wip1 protein activity;

[0012] (4) drugs that reduce Wip1 gene expression levels;

[0013] (5) Coro1a protein or its mutant protein;

[0014] (6) Reagents that promote the phosphorylation of Coro1a;

[0015] (7) Reagents for activating phospholipase C.

[0016] In some embodiments of the present invention, the drugs that inhibit the activity of Wip1 protein are GSK2830371 and CCT007093, which have inhibitory effects on Wip1 protein in both humans and mice.

[0017] The structural formula of GSK2830371 is shown in Formula I below,

[0018]

[0019] The structural formula of CCT007093 is shown in Formula II below,

[0020]

[0021] In some embodiments of the present invention, the reagent that promotes the phosphorylation of Coro1a is, for example, Phorbol 12-myristate 13-acetate (PMA) (ACMEC, 16561-29-8), whose structural formula is shown in the following formula III:

[0022]

[0024] In some embodiments of the present invention, the reagent for activating phospholipase C is, for example, m-3M3FBS (Santa Cruz Biotechnology, sc-202217), whose structural formula is shown in the following formula IV:

[0025]

[0026] In some embodiments of the present invention, in the use, the mammal is independently a human or a mouse.

[0027] In some embodiments of the present invention, the use, wherein the infectious disease is an infectious disease caused by bacteria, such as an infectious disease caused by Staphylococcus aureus, preferably an infectious disease caused by methicillin-resistant Staphylococcus aureus.

[0028] In some embodiments of the present invention, in the use, the infectious disease is skin abscess, such as skin abscess caused by Staphylococcus aureus, preferably skin abscess caused by methicillin-resistant Staphylococcus aureus.

[0029] In some embodiments of the present invention, the use, wherein the Wip1 protein is human or mouse Wip1 protein;

[0030] Preferably, the amino acid sequence of the Wip1 protein is as shown in SEQ ID NO:1 or SEQ ID NO:3.

[0031] In some embodiments of the present invention, the use, wherein the Wip1 gene is a human or mouse Wip1 gene;

[0032] Preferably, the sequence of the Wip1 gene is shown as SEQ ID NO:2 or SEQ ID NO:4.

[0033] In some embodiments of the present invention, the use, wherein the amino acid sequence of the domain is as shown in SEQ ID NO:5.

[0034] In some embodiments of the present invention, the use, wherein the sequence of the nucleic acid encoding the domain is as shown in SEQ ID NO:6.

[0035] In some embodiments of the present invention, in the use, the drug that inhibits the activity of Wip1 protein is selected from any one or more of GSK2830371 (MCE, HY-15832) and CCT007093 (MCE, HY-15880).

[0036] In some embodiments of the present invention, the use, wherein the drug that inhibits the activity of Wip1 protein is an antibody against Wip1 protein; preferably, the antibody is a monoclonal antibody against Wip1 protein, for example, Anti-PPM1D / WIP1antibody[EPR22960-39](Abcam, ab234439), Wip1 Antibody(F-10)(Santa Cruz Biotechnology, sc-376257).

[0037] In some embodiments of the present invention, the use, wherein the drug for reducing the expression level of the Wip1 gene is a polynucleotide for completely knocking out or partially knocking out the Wip1 gene; preferably, the polynucleotide is siRNA such as shRNA, or a guide RNA for the CRISPR / Cas9 system.

[0038] In some embodiments of the present invention, the use, wherein the amino acid sequence of the Coro1a protein is as shown in SEQ ID NO:7.

[0039] In some embodiments of the present invention, the use, wherein the mutant protein of the Coro1a protein is a mutant protein in which the serine at position 426 of the Coro1a protein is mutated to aspartic acid.

[0040] In some embodiments of the present invention, the use, wherein item (1) or item (2) serves as a target for drug action.

[0041] In some embodiments of the present invention, the use, wherein the Wip1 protein or its domain is the Wip1 protein or its domain in human neutrophils;

[0042] and / or

[0043] The Wip1 gene is the Wip1 gene in human neutrophils.

[0044] Another aspect of the present invention relates to an isolated polypeptide, whose amino acid sequence is shown in SEQ ID NO:5.

[0045] Another aspect of the present invention relates to an isolated nucleic acid encoding the isolated polypeptide of the present invention; preferably, the sequence of the isolated nucleic acid is shown in SEQ ID NO:6.

[0046] In some embodiments of the present invention, infectious diseases are treated by knocking out or inhibiting Wipl targets.

[0047] In some embodiments of the present invention, knocking out or inhibiting Wip1 targets promotes upregulation of neutrophil calcium ion pathways, increases formation of extracellular traps, and captures and kills pathogens.

[0048] In some embodiments of the present invention, knocking out or inhibiting Wip1 targets allows the accumulation of phosphorylated Coro1a, activates phospholipase C (PLC) activity, upregulates calcium ion pathways, and promotes NET formation.

[0049] Another aspect of the present invention relates to a method for preparing a method for treating or preventing an infectious disease in a mammal, comprising the step of administering an effective amount of any one of the above items (1) to (7) to a subject in need thereof.

[0050] Any one of the following (1) to (7), for use in treating or preventing an infectious disease in a mammal,

[0051] (1) Wip1 protein or its domain;

[0052] (2) a nucleic acid molecule encoding a Wip1 protein or a domain thereof;

[0053] (3) drugs that inhibit Wip1 protein activity;

[0054] (4) drugs that reduce Wip1 gene expression levels;

[0055] (5) Coro1a protein or its mutant protein;

[0056] (6) Reagents that promote the phosphorylation of Coro1a;

[0057] (7) Reagents for activating phospholipase C.

[0058] The inventions of this application are at least partially based on the following findings: Wip1 is involved in the bactericidal function of neutrophil NET release, and Wip1 knockout or inhibition can delay or prevent some pathological processes related to the neutrophil bacterial clearance function, such as the occurrence and development of infectious diseases.

[0059] The term "wild type p53-induced phosphatase 1 (Wip1, also known as PP2Cδ or PPM1D)" used in this application is a serine / threonine protein phosphatase belonging to the 2Cδ type protein phosphatase. At present, Wip1 from different species has been identified, for example: the gene accession number of the human Wip1 gene is NG_023265.1, and the NCBI link is: http: / / www.ncbi.nlm.nih.gov / gene / 8493; the gene accession number of the mouse Wip1 gene is: NC_000077.6, and the NCBI link is: http: / / www.ncbi.nlm.nih.gov / gene / 53892.

[0060] The term "neutrophil" used in this application is a type of white blood cell, usually accounting for 50%-75% of the total white blood cells, has antibacterial and phagocytic effects, is the first line of defense of natural immunity, and plays an important role in infectious diseases.

[0061] The term "neutrophil extracellular trap (NET)" used in this application refers to an inflammatory cell death mode discovered by Volker-Brinkmann and Arturo Zychlinsky in 2004, which can trap bacteria, fungi, protozoa and viruses. NETs are secreted by activated neutrophils and are composed of DNA fibers, histones and antimicrobial proteins. They can fix pathogens and expose them to local high lethal concentrations of effector proteins. It has been demonstrated that NETs can kill bacteria, thus defining a new antibacterial innate response (see, for example, "Neutrophil extracellular traps kill bacteria", Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A, Science, 2004Mar. 5;303(5663):1532-5.doi:10.1126 / science.1092385.PMID:15001782.), the above document is incorporated into this application by reference.

[0062] The term "methicillin-resistant Staphylococcus aureus" used in this application refers to a highly toxic bacterium that has broad-spectrum drug resistance, is resistant to β-lactam and cephalosporin antibiotics, has varying degrees of resistance to aminoglycosides, macrolides, tetracyclines, fluoroquinolones, sulfonamides, and rifampicin, is sensitive to vancomycin, has strong pathogenicity, can cause skin and soft tissue infections, blood infections, and infections of various organs throughout the body, and is one of the main pathogens of hospital and community infections.

[0063] Advantageous Effects of the Invention

[0064] The present invention provides an experimental basis and a new therapeutic target for the treatment of infectious diseases and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figures 1A to 1L Wip1 inhibitor GSK2830371 delayed the occurrence and development of skin abscesses in mice. Data are shown as mean ± standard deviation, * indicates p < 0.05, ** indicates p < 0.01. Among them:

[0066] Figure 1A : Mice were subcutaneously injected with 100 μL containing 5×10 7 The mouse skin abscess model was prepared with phosphate-buffered saline (PBS) solution containing CFU of Staphylococcus aureus. The Wip1 inhibitor-treated group was intragastrically administered with GSK2830371 (1 mg / mouse) every day, and the abscess sites of the mice were photographed, n = 5;

[0067] Figure 1B : The length (L) and width (W) of mouse skin abscesses were measured on days 0-10, and the abscess area was calculated [A = π (L / 2) × W / 2], n = 5;

[0068] Figure 1C : 48 hours after modeling, the skin tissue of the mouse abscess was taken, embedded in paraffin and sliced ​​(thickness 4 μm) for histopathological analysis by HE staining at magnifications of 40 and 100 times;

[0069] Figure 1D : The number of Staphylococcus aureus in the abscess 24 and 48 hours after infection;

[0070] Figure 1E to Figure 1G : The infiltration ratios of neutrophils (FVD-CD45+CD11b+Ly6G+) and macrophages (FVD-CD45+CD11b+F4 / 80+) 24 hours after infection;

[0071] Figure 1H : MPO content in serum 24 hours after infection;

[0072] Fig. 1I : ROS content in serum 24 hours after infection;

[0073] Figure 1J : dsDNA content in serum 24 hours after infection;

[0074] Figure 1K Neutrophils (5×10 4 cells / well), and the amount of NET formation (% of total DNA) was detected by SytoxGreen (2 μM) staining;

[0075] Figure 1L : Sytox Green (2 μM) staining was used to detect the formation of NETs induced by Staphylococcus aureus in vitro (% of total DNA).

[0076] FIG. 2A to FIG. 2F It shows that Wip1 mainly regulates the formation of neutrophil NETs to play an anti-infection role. The data are shown as mean ± standard deviation, * indicates p < 0.05, ** indicates p < 0.01. Among them:

[0077] Figure 2A : Mice were subcutaneously injected with 100 μL containing 5×10 7 The mouse skin abscess model was prepared by PBS solution containing CFU Staphylococcus aureus. The Wip1 inhibitor-treated group was intragastrically administered with GSK2830371 (1 mg / mouse) every day, and the NET inhibitor group was intravenously injected with DNaseI (10 μg / mouse) every day. The abscess sites of the mice were photographed, n=5;

[0078] Figure 2B : 48 hours after modeling, the skin tissue of the mouse abscess was taken, embedded in paraffin and sliced ​​(thickness 4 μm) for histopathological analysis by HE staining at magnifications of 40 and 100 times;

[0079] Figure 2C : The length (L) and width (W) of mouse skin abscesses were measured on days 0-10, and the abscess area was calculated [A = π (L / 2) × W / 2], n = 5;

[0080] Figure 2D : The number of Staphylococcus aureus in the abscess 24 and 48 hours after infection;

[0081] Figure 2E : The content of MPO-DNA complex in the abscess area;

[0082] Figure 2F:The content of dsDNA in serum was detected by Pico green staining.

[0083] FIG. 3A to FIG. 3I It was shown that loss / inhibition of Wip1 upregulated the calcium ion pathway in mouse / human neutrophils to enhance NET synthesis. Data are shown as mean ± standard deviation, * indicates p < 0.05, ** indicates p < 0.01. Among them:

[0084] Figure 3A : Bioinformatics analysis of the top 5 upregulated signal transduction pathways in LPS-stimulated Wip1 knockout (KO) neutrophils (Wip1KO_LPS) compared with LPS-stimulated wild-type (WT) neutrophils (WT_LPS), with the calcium ion pathway occupying a central position;

[0085] Figure 3B :Indo-1AM (2 μM) staining was used to detect intracellular Ca2+ in mouse neutrophils 2+ The cells were stimulated with 2 μM thapsigargin (Tg), CaCl2 (20 nM) and LPS (100 ng / mL) at 72 s, 234 s and 384 s, respectively. The ratio of fluorescence value 405 nm / 480 nm was the intracellular Ca 2+ concentration;

[0086] Figure 3C :Ca in human neutrophils 2+ Concentration detection;

[0087] Figure 3D :Immunofluorescence detection of NET synthesis in mouse bone marrow neutrophils treated with Wip1 inhibitor GSK2830371 (5 μM) or calcium channel inhibitor GdCl3 (1 μM) stimulated by LPS (1 μg / mL), magnified 63 times;

[0088] Figure 3E Mouse neutrophils (5×10) treated with Wip1 inhibitor GSK2830371 (5 μM) or calcium channel inhibitor GdCl3 (1 μM) were stimulated with LPS (1 μg / mL). 4 cells / well) for 3 h, and the formation of NETs (% of total DNA) was detected by Sytox Green (2 μM) staining;

[0089] Figure 3F :Sytox Green (2μM) staining method was used to detect the effect of calcium channel inhibitor GdCl3 (1μM) on Wip1-inhibited human neutrophil NET formation (% of total DNA);

[0090] Figure 3G:Immunofluorescence detection of LPS-induced NET synthesis in human neutrophils, magnified 63 times;

[0091] FIG. 3H to FIG. 3I : Sytox Green (2 μM) was used to detect the synthesis of NETs (% of total DNA) in human neutrophils stimulated with LPS (1 μg / mL) or PMA (50 nM).

[0092] FIG. 4A to FIG. 4E It shows that Wip1 regulates calcium ion pathway by dephosphorylating the Ser426 amino acid residue of its novel substrate Coro1a. The data are shown as mean ± standard deviation, * indicates p < 0.05, ** indicates p < 0.01. Among them:

[0093] Figure 4A :Protein spectrum analysis was performed on proteins that interacted with Myc-tagged Wip1 protein, phosphorylation protein spectrum analysis and genomic microarray analysis were performed on neutrophils of WT, WT-LPS, Wip1KO, and Wip1KO-LPS mice, and the proteins measured by protein spectrum and phosphorylation protein spectrum were intersected, and a total of 5 intersecting proteins were found. The genomic microarray found a total of 12 proteins that were both stimulated by LPS and regulated by the Wip1 gene. The proteins obtained by the three analysis methods were intersected, and a total of 5 phosphorylated proteins that were regulated by LPS and Wip1 and interacted with Wip1 were found.

[0094] Figure 4B :Network analysis of the regulatory role of these five proteins in signaling pathways;

[0095] Figure 4C :WB detection and analysis of in vitro phosphorylation experiment and GST-Pull down experiment;

[0096] Figure 4D :Regulatory effects of Coro1a and its mutant proteins on PLC activity in HEK293T cells;

[0097] Figure 4E :Effects of Coro1a and its mutant proteins on intracellular Ca2+ in HEK293T cells 2+ Concentration regulation.

[0098] FIG. 5A to FIG. 5G It shows that the amino acid sequence of Wip1 protein 28-90 is the key functional domain regulating PLC activity and NET formation. Data are shown as mean ± standard deviation; * indicates p < 0.05, ** indicates p < 0.01. Among them:

[0099] Figure 5A :Regulatory effect of Wip1 inhibition on PLC activity of human neutrophils;.

[0100] Figure 5B :Effects of Wip1 knockout on PLC activity in HL60 cell line;

[0101] Figure 5C :WB detection analysis of the interaction between Wip1 and its truncated proteins and Coro1a protein in HEK293T cell line. The truncated sequences of Wip1: ΔA, 1-101 amino acids; ΔB, 28-90 amino acids; ΔC, 516-591 amino acids; ΔD, 591-605 amino acids; E, 1-101, 516-605 amino acids;

[0102] Figure 5D Effects of Wip1 knockout or Wip1-ΔB knockout on intracellular Ca2+ in HL60 cell lines 2+ Effect of concentration;

[0103] Figure 5E :The effect of overexpression of Wip1 protein or Wip1-ΔB protein in Wip1 knockout HL60 cell line on PLC activity of HL60 cells;

[0104] Fig. 5F :Sytox Green (2 μM) staining method was used to detect the effect of overexpression of Wip1 protein or Wip1-ΔB protein in Wip1 knockout HL60 cell line on NET formation (% of total DNA) in HL60 cells;

[0105] Figure 5G :Immunofluorescence detection of the effect of overexpressing Wip1 protein or Wip1-ΔB protein on NET formation in Wip1 knockout HL60 cell line, magnified 63 times.

[0106] The partial sequence involved in the present invention is as follows:

[0107] 1. Human Wip1 protein amino acid sequence (605aa):

[0108] MAGLYSLGVSVFSDQGGRKYMEDVTQI VVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGP AVAAREARDPLPDAGASPAPSRCCRRRSSVAFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHNGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGEFVVSPEPDTSVHTLDPQKHKYIILGSDGLWNMIPPQDAISMCQDQEEKKYLMGEHGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELYLNLTDSPSYNSQETCVMTPSPCSTPPVKSLEEDPWPRVNSKDHIPALVRSNAFSENFLEVSAEIARENVQGVVIPSKDPEPLEENCAKALTLRIHDSLNNSLPIGLVPTNSTNTVMDQKNLKMSTPGQMKAQEIERTPPTNFKRTLEESNSGPLMKKHRRNGLSRSSGAQPASLPTTSQRKNSVKLTMRRRLRGQKKIGNPLLHQHRKTVCVC(SEQ ID NO:1)

[0109] 2. Human Wip1 coding nucleic acid sequence (1818 nt):

[0110] ATGGCGGGGCTGTACTCGCTGGGAGTGAGCGTCTTCTCCGACCAGGGCGGGAGGAAGTACATGGAGGACGTTACTCAAATC GTTGTGGAGCCCGAACCGACGGCTGAAGAAAAGCCCTCGCCGCGGCGGTCGCTGTCTCAGCCG TTGCCTCCGCGGCCGTCGCCGGCCGCCCTTCCCGGCGGCGAAGTCTCGGGGAAAGGCCCAGCGTGGCAGCCCGAG AGGCTCGCGACCCTCTCCCGGACGCCGGGGCCTCGCCGGCACCTAGCCGC

[0111] 3. Amino acid sequence of mouse Wip1 protein (598aa):

[0112] MAGLYSLGVSVFSDQGGRKYMEDVTQI VVEPEPAAEDKPAPVPRRALGLPATPTLAGVGPSEKGPAAA RDPAPDAAASLPAGRCCRRRSSV AFFAVCDGHGGREAAQFAREHLWGFIKKQKGFTSSEPAKVCAAIRKGFLACHLAMWKKLAEWPKTMTGLPSTSGTTASVVIIRGMKMYVAHVGDSGVVLGIQDDPKDDFVRAVEVTQDHKPELPKERERIEGLGGSVMNKSGVNRVVWKRPRLTHSGPVRRSTVIDQIPFLAVARALGDLWSYDFFSGKFVVSPEPDTSVHTLDPRKHKYIILGSDGLWNMVPPQDAISMCQDQEEKKYLMGEQGQSCAKMLVNRALGRWRQRMLRADNTSAIVICISPEVDNQGNFTNEDELFLNLTDSPTYNSQETCVMTSSPSSTPPIKSPEEDAWPRLSSKDHIPALVRSNAFSEKFLEVPAEIARGNIQTVVMTSKDSETLEENCPKALTLRIHDSLNNTLSVGLIPTNSTNTIMDQKNLKMSTPGQMKAQEVERTPPANFKRTLEESNSGPLMKKHRRNGLSRSSGAQASSLPTASQRRHSVKLTLRRRLRGQRKMGNPLLHQHRKTVCVC (SEQ ID NO:3)

[0113] 4. Nucleic acid sequence encoding mouse Wip1 (1797nt):

[0114]

[0115] 5. Human Wip1 protein domain

[0116] VVEPEPTAEEKPSPRRSLSQPLPPRPSPAALPGGEVSGKGPAV AAREARDPLPDAGASPAPSR(SEQID NO:5)

[0117] 6. Coding sequence of human Wip1 protein domain

[0118] GTTGTGGAGCCCGAACCGACGGCTGAAGAAAAGCCCTCGCCGCGGCGGTCGCTGTCTCAGCCGTTGCCTCCGCGGCCGTCGCCGGCCGCCCTTCCCGGCGGCGAAGTCTCGGGGAAAGGCCCAGCGGTGGCAGCCCGAGAGGCTCGCGACCCTCTCCCGGACGCCGGGGCCTCGCCGGCACCTAGCCGC(SEQ ID NO:6)

[0119] 7. Amino acid sequence of human Coro1a protein (461aa):

[0120] MSRQVVRSSKFRHVFGQPAKADQCYEDVRVSQTTWDSGFCAVNPKFVALICEASGGGAFLVLPLGKTGRVDKNAPTVCGHTAPVLDIAWCPHNDNVIASGSEDCTVMVWEIPDGGLMLPLREPVVTLEGHTKRVGIVAWHTTAQNVLLSAGCDNVIMVWDVGTGAAMLTLGPEVHPDTIYSVDWSRDGGLICTSCRDKRVRIIEPRKGTVVAEKDRPHEGTRPVRAVFVSEGKILTTGFSRMSERQVALWDTKHLEEPLSLQELDTSSGVLLPFFDPDTNIVYLCGKGDSSIRYFEITSEAPFLHYLSMFSSKESQRGMGYMPKRGLEVNKCEIARFYKLHERRCEPIAMTVPRKSDLFQEDLYPPTAGPDPALTAEEWLGGRDAGPLLISLKDGYVPPKSRELRVNRGLDTGRRRAAPEASGTPSSDAVSRLEEEMRKLQATVQELQKRLDRLEETVQAK(SEQ ID NO:7)

[0121] 8. Human Coro1a encoding nucleic acid sequence (1386nt):

[0122] DETAILED DESCRIPTION

[0123] The embodiments of the present invention will be described in detail below in conjunction with the examples, but those skilled in the art will appreciate that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If no specific conditions are specified in the examples, they are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0124] Materials and methods

[0125] Wip1 knockout (KO) mice

[0126] Wip1 knockout (KO) mice were provided by the Key Laboratory of Comparative Medicine of Human Diseases, Ministry of Health (Beijing, China). The inventors backcrossed Wip1KO mice to a C57BL / 6 background. All mice were housed in a specific pathogen-free animal facility at the Institute of Zoology, Chinese Academy of Sciences. Experiments were mainly conducted using sex-matched littermates aged 8-12 weeks. The primer sequences for identification of Wip1 knockout mice are shown in the following table:

[0127]

[0128] During genotyping identification, primer 1, primer 2, primer 3, and primer 4 need to be added to the identification reaction system at the same time to jointly identify the genotype.

[0129] Preparation and treatment of mouse skin abscess model

[0130] The inventors used methicillin-resistant Staphylococcus aureus (ATCC, 43300) to induce a mouse skin abscess model. Briefly, C57BL / 6 mice were anesthetized by intraperitoneal injection of pentobarbital, the mice were shaved and the skin was disinfected, and 100 μL of 5×10 7 The PBS suspension of CFU of Staphylococcus aureus was injected into the control group with 100 μL PBS as a control. The Wip1 inhibitor-treated group was intragastrically administered with 1 mg / mouse GSK2830371 daily. The mice in the NET inhibitor-treated group were intravenously injected with 10 μg of deoxyribonuclease I (DNaseI) daily starting from day 0. The length (L) and width (W) of the abscess lesion were measured every day, and the abscess area [A = π (L / 2) × W / 2] was calculated. The number of Staphylococcus aureus in the skin abscess was measured by the agar plate counting method.

[0131] Hematoxylin-eosin (HE) staining

[0132] Mouse skin tissue was fixed in formalin (10%, RNase-free, pH 7.2-7.4) for 12 h, then dehydrated, transparent, waxed, embedded and sliced ​​to 4 μm. The samples were stained with HE. HE staining images were scanned by a panoramic tissue cell analyzer (Leica aperio vesa8), and the skin tissue pathological characteristics were analyzed by Imagescope x64 software.

[0133] Flow cytometry

[0134] Cell suspensions of mouse abscess skin cells were prepared, and the proportion of neutrophils and macrophages in mouse skin abscesses was analyzed by flow cytometry. FVD780, anti-mCD45-APC (Biolegend, 103112), anti-mLy6G-PE-cy5 (Biolegend, 108409), anti-mCD11b-BV510 (Biolegend, 101263), and anti-mF4 / 80-FITC (Invitrogen, 11-4801-81) antibodies were added and incubated at 4°C for 30 minutes in the dark. Before flow cytometric analysis, cells were washed three times with PBS containing 0.1% (w / v) bovine serum albumin (BSA) and 0.1% NaN3. FACSCalibur (BD Biosciences) was used for flow cytometry detection, and data analysis was performed using FlowJo version 7.6.5.

[0135] Mouse neutrophil isolation

[0136] Mice were anesthetized with pentobarbital, and the femur, tibia, and ilium were isolated in a sterile environment. The bone marrow cavity was repeatedly flushed with sterile PBS to obtain bone marrow cells. Mojosort was used to TM Neutrophils (CD11b + 6G + Cells). Annexin V staining was used to analyze cell activity. The inventors used a flow cytometry sorting system to separate neutrophils from mouse skin abscesses. Skin tissue from the abscess was taken, and 4 mL of tissue digestion lysis buffer (a 500:1 mixture of collagenase IV and DNase I) was added for digestion, incubated at 37°C for 40 minutes, and undigested tissue residues were removed by filtration. The filtrate was centrifuged at 5000 rpm for 5 minutes to collect cells. Anti-mouse CD45-APC and anti-mouse Ly6G-PE-cy5 antibodies were used to incubate cells at 4°C in the dark for 30 minutes. Flow cytometry sorting of CD45 + 6G + Neutrophils. The purity of sorted neutrophils is greater than 99%.

[0137] Acquisition of human peripheral blood neutrophils

[0138] Blood samples were obtained from two healthy male volunteers aged 25 years, and written informed consent was obtained. This study was approved by the Ethics Committee of the General Hospital of the Chinese People's Liberation Army in accordance with the Declaration of Helsinki. 10 mL of peripheral blood was collected from each volunteer by venipuncture using K2 ethylenediaminetetraacetic acid (EDTA) blood collection tubes. Neutrophils were isolated using a neutrophil isolation kit (STEMCELL TECHNOLOGIES, 17957) and an immune cell sorting system, and CD45 was detected by flow cytometry. + CD15 + CD16 + The purity of neutrophils was greater than 99%.

[0139] Induction of neutrophil extracellular traps

[0140] Mouse neutrophils (according to the above “ Mouse neutrophil isolation " method), human neutrophils (obtained according to the aforementioned " Acquisition of human peripheral blood neutrophils ” method) or HL60 cell line (Cybex, iCell-h098), cultured in serum-free RPMI-1640 medium (including 2mM L-glutamine, 100U / mL penicillin and 100mg / mL streptomycin), and pre-cultured in a 37°C, 5% CO2 incubator for 2 hours with or without the addition of Wip1 inhibitor GSK2830371 (5μM) and calcium channel inhibitor GdCl3 (1μM). To trigger NET formation, 1×10 6 cells / mL density of neutrophils for 3 hours, or stimulated with Staphylococcus aureus at a multiplicity of infection (MOI) = 5 for 0, 1, 2, and 4 hours.

[0141] Analysis of NET synthesis by Sytox Green staining

[0142] The amount of NET synthesis (% of total DNA) was measured using Sytox Green, a DNA-binding dye that is impermeable to living cells. 4Neutrophils were inoculated into 96-well plates and 2 μM Sytox Green dye was added to quantify the formation of NETs. The fluorescence values ​​of excitation light 504 nm and emission light 523 nm were read using a microplate reader CYTATION-5 (BioTeK). The inventors defined the fluorescence intensity value of neutrophils treated with 1% (w / v) Triton X-100 as 100% total DNA release. The ratio of the fluorescence intensity value read at each time point to 100% total DNA represents the number of NETs formed (% of total DNA).

[0143] Immunofluorescence detection of NETs

[0144] NETs were photographed using a laser confocal microscope. 100 μL of 1×10 6 Human or mouse neutrophils or HL60 cells at 1:100 cells / mL were inoculated into poly-lysine-coated confocal culture dishes with a diameter of 35 mm to induce NET. Cells were fixed with 4% paraformaldehyde and strong staining permeabilization solution for 30 minutes. Cells were washed three times with PBS containing 3% BSA and 0.5% TritonX-100, and blocked with 5% fetal bovine serum (FBS) at 37°C for 60 minutes. NET components were incubated with donkeyanti-mouse-MPO (1:50) or MPO mouse monoclonal Antibody (1:50), rabbit monoclonal Histone H3 (citrulline R17) antibody (1:100) in primary antibody diluent at 4°C in the dark for 12 hours. Then, the cells were washed three times with PBS containing 3% BSA and 0.5% TritonX-100, and secondary antibodies donkey anti-mouseIgG(H+L)highly cross-adsorbed secondary antibody-Alexa fluor 568(1:1000) and donkey anti-rabbit IgG(H+L)highly cross-adsorbed secondary antibody-Alexafluor 488(1:1000) were added and incubated at 37°C for 2 hours. The washing solution was repeatedly washed three times to remove excess dye, and 4',6-diamino-2-phenylindole (DAPI) (1:1000) was added to stain the cell nucleus. Images were collected using a multi-mode microscopy imaging platform (AndorDragonfly).

[0145] Serum dsDNA testing

[0146] The inventors used Pico Green dye to detect the content of dsDNA in mouse serum. Pico Green is an extremely sensitive fluorescent nucleic acid dye that emits fluorescence after binding to double-stranded DNA. According to the dsDNA HS assay kit According to the instructions of YEASEN (12642ES60), the dsDNA detection agent was diluted to 1× with 100 μL dsDNA buffer and 20 μL serum was added. The dsDNA content was detected using qubit 4.0 (Thermo Scientific).

[0147] MPO-DNA complex detection

[0148] The inventors quantified the content of NET in the tissue by detecting the content of MPO-DNA complex in abscesses according to the instructions of the mouse MPO-DNA complex ELISA kit (enzyme-immune, MM-1177M2). In short, 1 g of mouse skin was ground in 1 mL of PBS buffer with an electric grinder. 10 μL of homogenate supernatant was added to a 96-well plate coated with MPO-DNA antibody and incubated at 37 ° C for 30 minutes. After repeated washing, 50 μL of horseradish peroxidase (HRP)-conjugated reagent was added and incubated at 36 ° C for 30 minutes. The reaction was stopped by adding color developing solutions A and B. The optical density (OD) at 450 nm was immediately detected with an enzyme standard meter, and the content of the MPO-DNA complex was calculated according to the standard curve.

[0149] Western Blot (WB)

[0150] Western blot was used to analyze protein expression levels. Samples were lysed with sodium dodecyl sulfate (SDS) lysis buffer, incubated on ice, shaken every 30 seconds for 3 minutes, and transferred to a 100°C water bath to denature the protein. Protein concentration was calibrated using a bicinchoninic acid (BCA) protein quantification kit (Thermo Scientific, 23225). TMNewflash protein anyKD PAGE was performed at 100V, 70mA for about 1-1.5 hours. The target band on the protein gel was transferred to a 0.2μm pore size PVDF membrane, and the PVDF membrane with the target protein was incubated with the primary antibody at 4°C overnight. The dilution ratios of the primary antibodies were as follows: Anti-β-actin mAb (Cell Signaling Technology, 48938S) (1:20000), anti-Histone H3 mAb (Abcam, ab219407) (1:1000), anti-Wip1 mAb (Cell Signaling Technology, 94886S) (1:1000), anti-Coro1a-mAb (Proteintech, 17760-1-AP-150UL) (1:1000), anti-Flag-tag mAb (Sigma-Aldrich, F7425) (1:2000), anti-Myc-tag mAb (Cell Signaling Technology, 2276S) (1:2000), anti-GST-mAb (Jinple, P01L074) (1:5000), anti-p-SerPKC substrate mAb (Cell Signaling Technology, 1 Technology, 6967s) (1: 1000), and anti-His-tag mAb (MBL, D291-3S) (1: 2000). The PVDF membrane incubated with primary antibody was placed in TBST washing solution and washed on a shaker for 30 minutes to remove excess unbound primary antibody. Then it was incubated with HRP-conjugated anti-mouse secondary antibody (Invitrogen, 31430) or anti-rabbit secondary antibody (Invitrogen, 31460) (1: 10000) at room temperature for 2 hours. The protein bands were visualized by enhanced ECL luminescent solution, and the protein band images were collected using the Tanon 1600R gel imaging system (Tanon).

[0151] Intracellular Ca 2+ Flow Detection

[0152] Indo-1AM dye was used to detect intracellular Ca 2+ Concentration. 100 μL density is 4×10 5 Mouse / human neutrophils or HL60 cells at 100 cells / mL were plated in a 96-well plate, and the cells were washed three times with calcium-free buffer, and 2 μM Indo-1AM and 10% pluronic F127 were added and incubated at room temperature for 40 minutes to bind Ca 2+The cells were washed three times with calcium-free buffer and left to stand for 10 minutes to allow Indo-1AM to fully bind. The intracellular Ca was then detected using an enzyme kinetics assay using a microplate reader CYTATION-5 (BioTeK). 2+ The fluorescence value was read every 9 seconds. The fluorescence values ​​at 405nm and 480nm were read respectively, and the ratio of 405nm / 480nm was the instantaneous intracellular Ca 2+ At time points 72s, 234s, and 384s, thapsigargin (2μM), CaCl2 (20mM), LPS (100ng / mL), or ionomycin (2μM) were added to detect the effects of different stimuli on intracellular Ca 2+ The influence of concentration.

[0153] PLC activity detection

[0154] According to the instructions of the phospholipase C (PLC) activity detection kit (Boxbio, AKFA015C), the activity of PLC was characterized by the change of OD value. 1 mL of the extract was mixed with 5 million cells, and then the cells were dissolved by ultrasonic vibration to prepare a crude extract enzyme solution. After adding the substrate and reacting for 30 minutes, the OD value at 410 nm was detected using a microplate reader cycle-5 (BioTek), and the PLC activity was calculated according to the standard curve.

[0155] Construction of overexpression plasmid and overexpression cell line

[0156] According to Hieff Wip1, Coro1a, Coro1Ser2A, Coro1aSer2D, Coro1aSer426A, and Coro1Ser426D were assembled into the pcDNA3.1-Myc-C vector according to the instructions of the Plus Multi-One Step Cloning Kit (YEASEN, 10912ES10). PPM1D, ΔA, ΔB, ΔC, ΔD, and E were then assembled into the pcDNA3.1-3×flag-C vector. To construct an HL60 cell line overexpressing Wip1 protein, the full-length cDNA encoding human Wip1 was amplified and inserted into the pCDH CMV Puro vector. Lentiviral particles for Wip1 overexpression were synthesized by co-transfecting the pCDH-CMV-Puro-wip1 vector with the packaging plasmids pMD2.G and pAS MAX into human embryonic kidney cells (HEK293T). The collected virus was used to infect HL60 cells, and puromycin was used to select to generate HL60 cell lines that stably expressed Wip1. For the construction of overexpression cell lines by electroporation, 2 μg of plasmid was added to 100 μL single Nucleocuvette TMThe cells were placed in an electroporation system and added to the electroporation instrument together with HL60 cells. The electroporation program was EN-138. WB detection was used to verify the overexpression of the protein.

[0157] Construction of Wip1KO HL60 cell line

[0158] To construct the Wip1KO HL60 cell line, the lent-CRISPRv2-sgPPM1D-Puro vector was constructed. The vector and packaging plasmid were co-transfected into HL60 cells using 3000 transfection reagent. Viruses were collected on the third day and used to infect HL60 cells. Cells were selected with puromycin for 5 days. Wip1KO HL60 cell lines were identified using WB analysis. sgRNA sequence:

[0159] sg:5′-AACCTTAGCGCTCGGACG-3′ (SEQ ID NO:13),

[0160] sgC: 5′-GTGTAGTTCGACCTATTCGTG-3′ (SEQ ID NO: 14).

[0161] Co-immunoprecipitation (Co-IP) and GST pull down analysis

[0162] Lyse the cells on ice for 1 hour with NETN buffer (containing 20mM Tris HCl [pH8.0], 100mM NaCl, 1mM EDTA, and 0.5% NP-40) containing 1× protease inhibitors. Remove the precipitate by repeated centrifugation, and then add 2μg of target protein antibody to the cell lysate and incubate overnight at 4℃. The next day, incubate the lysate with 30μL protein G / A agarose beads at 4℃ for 6 hours. For Co-IP experiments of proteins tagged with Flag, Myc, etc., the cell lysate is incubated with anti- Incubate with M2affinity beads or anti-Myc beads at 4℃ for 12 hours. Collect beads bound to proteins and analyze by WB. For GST pull down analysis, construct a GST-tagged prokaryotic expression vector and express the GST-tagged fusion protein in E. coli. Purify and obtain high-purity GST fusion protein by glutathione sepharose 4B beads. Detect protein expression and interacting proteins by WB.

[0163] Protein profiling

[0164] The protein peptide mixture was separated and analyzed by Nanoflow C18 reverse phase chromatography, using a 15 cm fused silica monolithic column and an Easy n-LC nano-liquid chromatograph loaded with an electrospray ion source and LTQ Orbitrap MS for detection. The sample was run at a flow rate of 800 nL / min for 30 minutes, and the peptides were eluted using a gradient eluent (80% acetonitrile, 2.5% isopropanol, 0.5% acetic acid). Positive ion mode operation was performed by automatically switching between MS and MS / MS acquisition modes. The separated precursor ions and all neutral loss fragments were stored simultaneously to generate a composite mass spectrum for peptide identification.

[0165] Genomic microarray analysis

[0166] WT and Wip1KO mice were euthanized by intraperitoneal injection of 1% sodium pentobarbital. Mouse bone marrow cells were obtained and divided into four groups according to whether LPS (100 ng / mL) was added: WT, WT-LPS, Wip1KO, and Wip1KO-LPS. Total cellular RNA was extracted by Trizol and purified using RNAeasy mini kit (Qiagen, 74104). The concentration and quality of RNA were detected by nanodrop 2000. The collected mRNA was reverse transcribed into cDNA (1 μg) and fluorescently labeled, and then hybridized to a mouse genomic oligonucleotide microarray (4×44K, Agilent Technologies). The chip was scanned by a microarray scanner (G2565BA, Agilent Technologies).

[0167] Statistical analysis

[0168] All data are presented as mean ± SD. Data containing only two group means were analyzed using unpaired two-tailed Student's t test. Data containing multiple group means were tested using one-way analysis of variance (ANOVA) using SAS version 9.2. When the P value was less than or equal to 0.05, the difference between groups was considered statistically significant.

[0169] Example 1: Inhibition of Wip1 can attenuate the formation of skin abscesses in mice induced by Staphylococcus aureus

[0170] The present inventors first studied the effects of the Wip1 inhibitor GSK2830371 on abscess healing and NET formation in mice caused by Staphylococcus aureus.

[0171] The inventors used methicillin-resistant Staphylococcus aureus strains to induce mouse skin abscess model, and selected C57BL / 6 male mice, 6-8 weeks old, weighing 22±2g, and divided them into four groups: PBS control group, GSK2830371 group, abscess model group and GSK2830371 abscess model group; each group had 5 mice.

[0172] One day before the skin abscess model was established, the GSK2830371 group and the GSK2830371 abscess model group were given the inhibitor GSK2830371 (1 mg / mouse) by gavage, and the other two groups were given the same volume of PBS by gavage. On Day 0, after the mice were anesthetized by intraperitoneal injection of pentobarbital, the back was shaved and disinfected, and the skin of about 2 cm × 2 cm was exposed. In the abscess model group and the GSK2830371 abscess model group, 100 μL containing 5×10 7 The bacterial solution of CFU was subcutaneously injected into the back of mice, and the PBS control group and GSK2830371 group were injected with the same volume of PBS. The length (L) and width (W) of the mouse abscess were measured every day, and the abscess area (A) was calculated, the formula A = π (L / 2) × W / 2. 24 hours after modeling, the skin tissue of the mouse abscess was taken, and the single cell suspension was prepared. The infiltration ratio of neutrophils and macrophages was detected by flow cytometry to observe the infiltration of inflammatory cells. At the same time, the mouse serum was taken to detect the indicators related to NET formation such as MPO, ROS, and dsDNA in the peripheral blood. 48 hours after modeling, the skin tissue of the mouse abscess was taken for HE histopathological examination to observe the size of the abscess and the infiltration of inflammatory cells.

[0173] The results showed that compared with the control group, inhibition of Wip1 could delay subcutaneous abscess formation and promote abscess healing (P<0.01, Figure 1A , Figure 1B Skin histopathological examination at 48 hours after infection revealed that compared with the control group, the number of inflammatory cells infiltrating the abscesses in mice treated with Wip1 inhibitors was reduced, and the abscess area was significantly reduced (P<0.01, Figure 1C ).

[0174] In addition, the number of Staphylococcus aureus in the abscess was significantly reduced after treatment with Wip1 inhibitor (P < 0.01, Figure 1D Flow cytometric analysis showed that 24 hours after infection, Wip1-inhibited mice recruited more CD45 + CD11b + 6G + Neutrophils to the abscess site (P<0.01, Figure 1E , Figure 1F ), and at this time point, CD45 + CD11b + F4 / 80 + There was no difference in the number of macrophages (Figure P>0.05, Figure 1E , Figure 1GAt the same time, 24 hours after S. aureus infection, the indicators related to NET formation, such as myeloperoxidase (MPO), NOX2-derived reactive oxygen species (ROS), and dsDNA, in the serum of Wip1-inhibited mice were significantly increased compared with those in the control group (P<0.01, Figures 1H to 1K ).

[0175] To detect the difference in NET formation by neutrophils in abscesses of mice treated with Wip1 inhibitor, the present inventors used flow cytometry to sort neutrophils from skin abscesses of control and Wip1-inhibited mice, and cultured these cells in vitro for 3 hours. Sytox Green staining showed that NET formation by neutrophils isolated from Wip1-inhibited mice was enhanced (P<0.01, Figure 1K ).

[0176] In order to observe the direct effect of Wip1 inhibitor on NET induced by S. aureus, the present inventors stimulated mouse bone marrow neutrophils with S. aureus (MOI=5) at different time points and found that Wip1 inhibition significantly enhanced the formation of NET (P<0.01, Figure 1L ).

[0177] Therefore, the inventors believe that inhibiting Wip1 can kill Staphylococcus aureus by enhancing the formation of neutrophil NETs and delay the formation of skin abscesses in mice.

[0178] Example 2: Wip1 slows down abscess formation mainly by regulating NET formation

[0179] In order to verify whether Wip1 is involved in the disease progression of skin abscesses by regulating the generation of NETs, ​​starting from Day 0, infected mice in the control group (same as Example 1) and the Wip1 inhibition group (same as Example 1) were intravenously injected with NET scavenger DNaseⅠ (10 μg / mouse / day), and the survival of Staphylococcus aureus was observed.

[0180] The results showed that the inhibitory effect of Wip1 inhibitor on abscess formation was abolished after DNaseⅠ treatment ( Figure 2A ), including histopathological examination, also showed similar results ( Figure 2B ), the abscess area was basically the same as that of the control group treated with DNaseⅠ, with no statistical difference (P>0.05, Figure 2C DNase I treatment significantly reduced NET release in mice, as evidenced by a local decrease in MPO-DNA complexes in abscesses and a decrease in dsDNA levels in serum ( Figure 2D , Figure 2EDNase1 treatment reversed the clearance of S. aureus from the abscesses by Wip1 inhibitor, and the number was similar to that of the DNase1-treated control group (P>0.05, Figure 2F ).

[0181] These results suggest that inhibition of Wip1 can enhance the formation and release of NETs, ​​kill S. aureus, and thereby slow down the formation of skin abscesses.

[0182] Example 3: Wip1 deficiency or inhibition leads to upregulation of calcium ion pathways and promotes NET synthesis

[0183] In order to analyze the mechanism by which Wip1 regulates the formation of neutrophil NETs, ​​bone marrow neutrophils from WT and Wip1 KO mice were divided into a control group and an LPS (100 ng / mL) stimulation group. The total RNA of each group of cells was extracted and reverse transcribed into cDNA, and then analyzed using genomic microarray. The results showed that among the top 5 signal transduction pathways that were upregulated in LPS-stimulated Wip1KO neutrophils (Wip1KO_LPS) compared with LPS-stimulated wild-type neutrophils (WT_LPS), the calcium ion pathway occupied a central position ( Figure 3A ).

[0184] Therefore, the present inventors detected the intracellular Ca2+ expression in mouse / human neutrophils after Wip1 was inhibited. 2+ The results showed that after stimulation with thapsigargin (Tg), Wip1-inhibited mouse / human neutrophil endoplasmic reticulum Ca 2+ More can be released into the cell, and Ca is added to the reaction system 2+ After that, more extracellular calcium (extracellular calcium ions) enter the cytoplasm. LPS stimulation also causes more Ca2+ to accumulate in the cytoplasm of Wip1-inhibited neutrophils. 2+ ( Figure 3B , Figure 3C ).

[0185] Therefore, the present inventors gave mouse neutrophils the calcium channel inhibitor GdCl3 to further determine the role of calcium ion channels in Wip1 regulation of NET synthesis. The results showed that the calcium channel inhibitor eliminated the increase in NET synthesis caused by Wip1 inhibitor in response to LPS stimulation ( Figure 3D In the NET quantification experiment of Sytox Green staining, it was also observed that GdCl3 treatment reduced the release of NETs by neutrophils from Wip1-inhibited mice, regardless of the response to LPS ( Figure 3E ) or PMA( Figure 3F At the same time, the inventors also observed the same results in human neutrophils ( FIG. 3G to FIG. 3I ).

[0186] The above results indicate that the calcium ion pathway is the main pathway involved in regulating the increased NET release caused by Wip1 deficiency or inhibition.

[0187] Example 4: Wip1 regulates calcium ion flux by dephosphorylating the Ser426 residue of the novel substrate Coro1a road

[0188] Since Wip1 is a phosphatase, it often regulates cell functions by dephosphorylating a substrate. In order to explore the molecular mechanism of Wip1 regulating calcium ion pathways, the inventors used protein profiling, phosphorylated protein profiling and genomic microarray to jointly search for possible substrates of Wip1.

[0189] Protein spectrum analysis: Flag empty protein and flag-Wip1 protein were overexpressed in human 293T cell lines, and Flag magnetic beads were used to pull down all proteins bound to empty protein or wip1, and the two protein samples were subjected to protein spectrum analysis.

[0190] Phosphorylation protein spectrum analysis: Bone marrow neutrophils from WT and Wip1KO mice were divided into control group and LPS stimulation group, respectively. Phosphorylated proteins in cells were enriched with TiO2Phosphopeptide Enrichment Kit, and then phosphorylation protein spectrum analysis was performed.

[0191] Genome microarray: Bone marrow neutrophils from WT and Wip1KO mice were divided into control group and LPS stimulation group, respectively. Total RNA was extracted from cells, reverse transcribed into cDNA, and then subjected to genome microarray detection.

[0192] There are 5 overlapping proteins in the protein spectrum and phosphorylated protein spectrum. There are 12 genes regulated by LPS and Wip1 gene in the genomic microarray. The intersection of these 17 proteins shows that there are 5 phosphorylated proteins that bind to Wip1 and are regulated by LPS and Wip1 gene ( Figure 4A ). Analyzing the roles of these five proteins in the pathway regulated by Wip1, it was found that Coro1a is in a major position in regulating the signaling pathway ( Figure 4B ).

[0193] In order to verify whether Wip1 can directly act on Coro1a, the inventors purified prokaryotically expressed human Coro1a and site-specific mutant proteins. The results showed that Wip1 can interact with phosphorylated Coro1a, mainly phosphorylation of Ser426 ( Figure 4CThe inventors further tested the activation effect of Coro1a and its mutants on PLC and found that Coro1a and Ser426D (D is aspartic acid, which can simulate the continuous phosphorylation form of this point) phosphorylated by Protein kinase C (PKC) can significantly activate PLC ( Figure 4D ), and phosphorylation of Ser426 is the main phosphorylation site of Coro1a in regulating calcium ion channels ( Figure 4E ). The above data all indicate that Wip1 regulates the calcium ion pathway by dephosphorylating the Ser426 residue of the novel substrate Coro1a.

[0194] Example 5: The amino acid sequence of Wip1 protein 28–90 is a key functional domain regulating PLC activity and NET formation

[0195] In view of the above results, phosphorylated Coro1a can activate PLC enzyme activity and regulate calcium ion pathways. Therefore, the inventors identified the effect of Wip1 inhibition or deletion on PLC activity. The results showed that inhibition of Wip1 activity in human neutrophils or knockout of Wip1 in the HL60 cell line increased PLC enzyme activity when the cells were stimulated with LPS / ionomycin ( Figure 5A , Figure 5B ).

[0196] The inventors further explored the functional domains of Wip1 binding to Coro1a and found that the amino acid sequence of segment 28–90 (segment B) is the main functional domain for binding to Coro1a ( Figure 5C The mutant of Wip1 lacking the amino acid sequence of 28–90 (Wip1-ΔB) abolished the downregulation of calcium ion flow by Wip1 ( Figure 5D ), the amino acid sequence of 28–90 is the main functional domain of Wip1 that regulates calcium ions.

[0197] Therefore, the inventors constructed a Wip1KO HL60 cell line to further confirm whether the 28-90 amino acid sequence is the key functional domain of Wip1 in regulating NET. The results showed that after Wip1KO HL60 was stimulated by LPS, the PLC enzyme activity was significantly enhanced. Re-overexpression of the Wip1 overexpression plasmid reduced the PLC enzyme activity, while overexpression of Wip1 lacking the B segment (Wip1-ΔB) failed to downregulate the PLC enzyme activity ( Figure 5E ). Similarly, after Wip1 KO HL60 was stimulated by LPS, NET synthesis was significantly enhanced. Re-overexpression of the Wip1 overexpression plasmid reduced NET synthesis, while overexpression of Wip1 lacking segment B (Wip1-ΔB) failed to reduce NET synthesis ( Fig. 5F , Figure 5G ).

[0198] The above data indicate that the amino acid sequence 28–90 of Wip1 protein is the key functional domain that regulates PLC activity and NET formation.

[0199] Although the specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art. According to all the teachings disclosed, various modifications and replacements can be made to those details, and these changes are all within the protection scope of the present invention. The full scope of the present invention is given by the attached claims and any equivalents thereof.

Claims

1. Use of any one of the following (1) to (7) in the preparation of a medicament for treating or preventing an infectious disease in a mammal: (1) Wip1 protein or its domain; (2) a nucleic acid molecule encoding a Wip1 protein or a domain thereof; (3) drugs that inhibit Wip1 protein activity; (4) drugs that reduce Wip1 gene expression levels; (5) Coro1a protein or its mutant protein; (6) Reagents that promote the phosphorylation of Coro1a; (7) Reagents for activating phospholipase C.

2. The use according to claim 1, wherein The mammal is independently a human or a mouse.

3. The use according to any one of claims 1 to 2, wherein The infectious disease is an infectious disease caused by bacteria, such as an infectious disease caused by Staphylococcus aureus, preferably an infectious disease caused by methicillin-resistant Staphylococcus aureus.

4. The use according to any one of claims 1 to 3, wherein The infectious disease is a skin abscess, such as a skin abscess caused by Staphylococcus aureus, preferably a skin abscess caused by methicillin-resistant Staphylococcus aureus.

5. The use according to any one of claims 1 to 4, wherein The Wip1 protein is human or mouse Wip1 protein; Preferably, the amino acid sequence of the Wip1 protein is as shown in SEQ ID NO:1 or SEQ ID NO:

3.

6. The use according to any one of claims 1 to 3, wherein The Wip1 gene is a human or mouse Wip1 gene; Preferably, the sequence of the Wip1 gene is shown as SEQ ID NO:2 or SEQ ID NO:

4.

7. The use according to any one of claims 1 to 6, wherein The amino acid sequence of the domain is shown in SEQ ID NO:

5.

8. The use according to any one of claims 1 to 7, wherein The sequence of the nucleic acid encoding the domain is shown in SEQ ID NO:

6.

9. The use according to any one of claims 1 to 8, wherein The drug that inhibits the activity of Wip1 protein is selected from the compounds shown in Formula I or Formula II, 10. The use according to any one of claims 1 to 9, wherein The drug that inhibits the activity of Wip1 protein is an antibody against Wip1 protein; preferably, the antibody is a monoclonal antibody against Wip1 protein, for example, Anti-PPM1D / WIP1 antibody [EPR22960-39] (Abcam, ab234439), Wip1 Antibody (F-10) (Santa Cruz Biotechnology, sc-376257).

11. The use according to any one of claims 1 to 10, wherein The drug for reducing the expression level of the Wip1 gene is a polynucleotide for completely knocking out or partially knocking out the Wip1 gene; preferably, the polynucleotide is siRNA such as shRNA, or a guide RNA for the CRISPR / Cas9 system.

12. The use according to any one of claims 1 to 11, wherein The amino acid sequence of the Coro1a protein is shown in SEQ ID NO:

7.

13. The use according to any one of claims 1 to 12, wherein The mutant protein of the Coro1a protein is obtained by mutating the serine at position 426 of the Coro1a protein to aspartic acid.

14. The use according to any one of claims 1 to 13, wherein The reagent promoting the phosphorylation of Coro1a is a compound shown in formula III, 15. The use according to any one of claims 1 to 14, wherein The reagent for activating phospholipase C is a compound shown in formula IV, 16. The use according to any one of claims 1 to 15, wherein The item (1) or item (2) is used as the target of drug action.

17. The use according to any one of claims 1 to 16, wherein The Wip1 protein or its domain is the Wip1 protein or its domain in human neutrophils; and / or The Wip1 gene is the Wip1 gene in human neutrophils.

18. An isolated polypeptide, the amino acid sequence of which is shown in SEQ ID NO:

5.

19. An isolated nucleic acid encoding the isolated polypeptide according to claim 16; preferably, the sequence of the isolated nucleic acid is shown in SEQ ID NO: 6.

Citation Information

Patent Citations

  • Medical use of Wip1 inhibitor

    CN105727295A

  • IDENTIFICATION OF PPM1D MUTATIONS AS A NOVEL BIOMARKER FOR NAMPTi SENSITIVITY

    CN114096243A